Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. (Q34604396)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

review article

1 reference

title

Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Andrew Schally

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Jörg B Engel

series ordinal

1

1 reference

3 August 2017

1 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Endocrinology and Metabolism

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

157-167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

Hormone treatment of endometriosis: the estrogen threshold hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Hypothalamic Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH)-Regulating Hormone: Structure, Physiology, and Clinical Studies**The work described here has been supported by research grants from the Veterans Administration, United State

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Second gene for gonadotropin-releasing hormone in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Human type II GnRH receptor mediates effects of GnRH on cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Hypothalamic hormones and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

The gonadotrophin-releasing hormone receptor: signalling, cycling and desensitisation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Gonadotropin-Releasing Hormone (GnRH)-Binding Sites in Human Breast Cancer Cell Lines and Inhibitory Effects of GnRH Antagonists*

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Primary and salvage therapy with LH-RH analogues in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

A review of studies of hormonal adjuvant therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Intermittent Androgen Deprivation for Patients With Recurrent/Metastatic Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Rapid reduction of uterine myomas after short-term treatment with microencapsulated D-Trp6-LHRH

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide)

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Use of GnRH antagonists in the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Extrapituitary effects of GnRH antagonists in assisted reproduction: a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

GnRH antagonist in assisted reproduction: a Cochrane review

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Clinical suppression of precocious puberty with cetrorelix after failed treatment with GnRH agonist in a girl with gonadotrophin-independent precocious puberty

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

An association of elevated serum gonadotropin concentrations and Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0399

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0399

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17237842%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference